interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Rucaparib Camsylate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Rucaparib Camsylate, and who makes it?

Rucaparib Camsylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Rucaparib Camsylate1 dosage-form group in the Orange Book
0generic makers listed
  1. Rucaparib Camsylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Rubraca. No generic is listed as marketed.

2015202020252030203501brand 2016data datePatent 8143241 listed to expire 12 August 2027Patent 8071579 listed to expire 12 August 2027Patent 9861638 listed to expire 10 February 2031Patent 8754072 listed to expire 10 February 2031Patent 10278974 listed to expire 10 February 2031Patent 9045487 listed to expire 10 February 2031Patent 8859562 listed to expire 4 August 2031Patent 10130636 listed to expire 17 August 2035Patent 9987285 listed to expire 17 August 2035Exclusivity I-982 to 17 December 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 December 2028Exclusivity I-982 Rubraca
  • 12 August 2027Patent 8143241
  • 12 August 2027Patent 8071579
  • 10 February 2031Patent 9861638
  • 10 February 2031Patent 8754072 drug substance
  • 10 February 2031Patent 10278974 drug product
  • 10 February 2031Patent 9045487 drug substance
  • 4 August 2031Patent 8859562
  • 17 August 2035Patent 10130636

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.